Beurskens, Frank J <br/><br/>
Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.  [electronic resource] 

 -  Journal of immunology (Baltimore, Md. : 1950)  Apr 2012 
 - 3532-41 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1550-6606 
<br/><br/><label>Standard No.: </label>10.4049/jimmunol.1103693  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alemtuzumab<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived--administration & dosage<br/>Antibody-Dependent Cell Cytotoxicity<br/>Antigens, CD20--immunology<br/>Antigens, Neoplasm--immunology<br/>Antineoplastic Agents--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>B-Lymphocyte Subsets--drug effects<br/>Cell Line, Tumor--drug effects<br/>Combined Modality Therapy<br/>Complement Activation<br/>Complement C3b--analysis<br/>Complement C4b--analysis<br/>Complement System Proteins--immunology<br/>Cyclophosphamide--administration & dosage<br/>Cytotoxicity, Immunologic<br/>Humans<br/>Immunotherapy<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Lymphocyte Count<br/>Opsonin Proteins--immunology<br/>Rituximab<br/>Vidarabine--administration & dosage